Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Xenetic Biosciences stock

Own Xenetic Biosciences stock in just a few minutes.

Xenetic Biosciences, Inc is a biotechnology business based in the US. Xenetic Biosciences shares (XBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Xenetic Biosciences employs 4 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Xenetic Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – XBIO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Xenetic Biosciences share price

Use our graph to track the performance of XBIO stocks over time.

Xenetic Biosciences shares at a glance

Information last updated 2021-04-23.
52-week range$0.76 - $3.84
50-day moving average $2.23
200-day moving average $1.93
Wall St. target price$5.00
PE ratio 0.8151
Dividend yield N/A (0%)
Earnings per share (TTM) $-12.32

Buy Xenetic Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Xenetic Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Xenetic Biosciences under- or over-valued?

Valuing Xenetic Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xenetic Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Xenetic Biosciences's P/E ratio

Xenetic Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Xenetic Biosciences shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Xenetic Biosciences financials

Revenue TTM $436,942
Gross profit TTM $436,942
Return on assets TTM -16.9%
Return on equity TTM -74.03%
Profit margin 0%
Book value $1.40
Market capitalisation $16.7 million

TTM: trailing 12 months

Shorting Xenetic Biosciences shares

There are currently 96,873 Xenetic Biosciences shares held short by investors – that's known as Xenetic Biosciences's "short interest". This figure is 23.1% down from 125,985 last month.

There are a few different ways that this level of interest in shorting Xenetic Biosciences shares can be evaluated.

Xenetic Biosciences's "short interest ratio" (SIR)

Xenetic Biosciences's "short interest ratio" (SIR) is the quantity of Xenetic Biosciences shares currently shorted divided by the average quantity of Xenetic Biosciences shares traded daily (recently around 269091.66666667). Xenetic Biosciences's SIR currently stands at 0.36. In other words for every 100,000 Xenetic Biosciences shares traded daily on the market, roughly 360 shares are currently held short.

However Xenetic Biosciences's short interest can also be evaluated against the total number of Xenetic Biosciences shares, or, against the total number of tradable Xenetic Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xenetic Biosciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Xenetic Biosciences shares in existence, roughly 10 shares are currently held short) or 0.0121% of the tradable shares (for every 100,000 tradable Xenetic Biosciences shares, roughly 12 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Xenetic Biosciences.

Find out more about how you can short Xenetic Biosciences stock.

Xenetic Biosciences share dividends

We're not expecting Xenetic Biosciences to pay a dividend over the next 12 months.

Have Xenetic Biosciences's shares ever split?

Xenetic Biosciences's shares were split on a 1:12 basis on 24 June 2019. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Xenetic Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Xenetic Biosciences shares which in turn could have impacted Xenetic Biosciences's share price.

Xenetic Biosciences share price volatility

Over the last 12 months, Xenetic Biosciences's shares have ranged in value from as little as $0.76 up to $3.84. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenetic Biosciences's is 2.5262. This would suggest that Xenetic Biosciences's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Xenetic Biosciences overview

Xenetic Biosciences, Inc. , a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site